Orchestra Biomed Holdings Stock Probability of Future Stock Price Finishing Over 21.29
| OBIO Stock | 5.26 0.08 1.50% |
Orchestra |
Orchestra BioMed Target Price Odds to finish over 21.29
The tendency of Orchestra Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over 21.29 or more in 90 days |
| 5.26 | 90 days | 21.29 | close to zero percent |
Based on a normal probability distribution, the odds of Orchestra BioMed to move over 21.29 or more in 90 days from now is close to zero percent (This Orchestra BioMed Holdings probability density function shows the probability of Orchestra Stock to fall within a particular range of prices over 90 days) . Probability of Orchestra BioMed Holdings price to stay between its current price of 5.26 and 21.29 at the end of the 90-day period is about 63.89 .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.78 . This indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Orchestra BioMed will likely underperform. Additionally Orchestra BioMed Holdings has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Orchestra BioMed Price Density |
| Price |
Predictive Modules for Orchestra BioMed
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Orchestra BioMed Holdings. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Orchestra BioMed Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Orchestra BioMed is not an exception. The market had few large corrections towards the Orchestra BioMed's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Orchestra BioMed Holdings, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Orchestra BioMed within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.18 | |
β | Beta against Dow Jones | 1.78 | |
σ | Overall volatility | 0.45 | |
Ir | Information ratio | -0.02 |
Orchestra BioMed Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Orchestra BioMed for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Orchestra BioMed Holdings can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Orchestra BioMed had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 2.76 M. Net Loss for the year was (49.12 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Orchestra BioMed generates negative cash flow from operations | |
| About 22.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from MacroaxisInsider: Disposition of 34403 shares by Taylor Andrew Lawrence of Orchestra BioMed at 5.03 subject to Rule 16b-3 |
Orchestra BioMed Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Orchestra Stock often depends not only on the future outlook of the current and potential Orchestra BioMed's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Orchestra BioMed's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 33.2 M | |
| Cash And Short Term Investments | 87.6 M |
Orchestra BioMed Technical Analysis
Orchestra BioMed's future price can be derived by breaking down and analyzing its technical indicators over time. Orchestra Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Orchestra BioMed Holdings. In general, you should focus on analyzing Orchestra Stock price patterns and their correlations with different microeconomic environments and drivers.
Orchestra BioMed Predictive Forecast Models
Orchestra BioMed's time-series forecasting models is one of many Orchestra BioMed's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Orchestra BioMed's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Orchestra BioMed Holdings
Checking the ongoing alerts about Orchestra BioMed for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Orchestra BioMed Holdings help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Orchestra BioMed had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 2.76 M. Net Loss for the year was (49.12 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Orchestra BioMed generates negative cash flow from operations | |
| About 22.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from MacroaxisInsider: Disposition of 34403 shares by Taylor Andrew Lawrence of Orchestra BioMed at 5.03 subject to Rule 16b-3 |
Check out Orchestra BioMed Backtesting, Orchestra BioMed Valuation, Orchestra BioMed Correlation, Orchestra BioMed Hype Analysis, Orchestra BioMed Volatility, Orchestra BioMed History as well as Orchestra BioMed Performance. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Orchestra BioMed. If investors know Orchestra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Orchestra BioMed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.60) | Revenue Per Share 0.073 | Quarterly Revenue Growth 1.356 | Return On Assets (0.39) | Return On Equity (0.92) |
The market value of Orchestra BioMed Holdings is measured differently than its book value, which is the value of Orchestra that is recorded on the company's balance sheet. Investors also form their own opinion of Orchestra BioMed's value that differs from its market value or its book value, called intrinsic value, which is Orchestra BioMed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Orchestra BioMed's market value can be influenced by many factors that don't directly affect Orchestra BioMed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Orchestra BioMed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Orchestra BioMed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Orchestra BioMed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.